Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of carboplatin plus pemetrexed in HIV-positive patients with advanced nonsquamous non-small cell lung cancer
2010-023676-48Phase 2Completed
- Sponsor
- IFCT
- Start
- Nov 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and pemetrexed in non-small cell lung cancer (NSCLC) and human immunodeficiency virus infection (HIV), sponsored by IFCT. Primary endpoint: Disease control rate after 4 cycles. Started Nov 2010; status: completed.
02
Drugs
carboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2010-023676-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023676-48.